Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 145
- Registration Number
- NCT00267189
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
🇩🇪Novartis Investigational Site, Germany, Germany
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 49
- Registration Number
- NCT00255788
- Locations
- 🇨🇦
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 833
- Registration Number
- NCT00251004
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Polymorphism of the Cytochrome P450-system in Renal Transplants
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 200
- Registration Number
- NCT00223054
- Locations
- 🇩🇪
University of Schleswig-Holstein, Campus Kiel, Department of Nephrology, Kiel, Germany
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT00187174
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00170859
- Locations
- 🇩🇪
Novartis Investigational Site, Various Cities, Germany
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Registration Number
- NCT00170885
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00170820
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT00170833
Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00154310
- Locations
- 🇨🇭
Novartis Pharma AG, Basel, Switzerland
🇨🇭Novartis Investigational Sites, Bern, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.